ITRM - חוב כולל להון Iterum Therapeutics

Serving as confirmation of the market valuation, the Iterum Therapeutics plc (ITRM) debt-to-equity price chart stands at 0.00, complementing a development strategy for anti-infectives through partnerships with global research centers. The business relies on the creation of unique antibiotics, whose exclusivity and patent protection ensure a sustainable industry position. However, Iterum Therapeutics plc (ITRM) is struggling with stringent regulatory requirements and the threat of expansion from low-cost generics.

For Iterum Therapeutics plc (ITRM), which is scaling antibacterial sales in the global market, a total debt-to-equity ratio of 0.00 reflects the extent to which business development depends on borrowed funds. This metric, calculated as the quotient of total debt to equity, determines the issuer's financial resilience to external shocks, allowing investors to assess the balance between credit leverage and the company's own resources.